机译:放射性碘治疗难治性转移灶出现后分化型甲状腺癌的预后及预后因素
Department of Surgery, Clinical Trial Management Center, Kuma Hospital, 8-2-35, Shimoyamate-Dori, Chuo-ku, Kobe 650-0011, Japan;
Clinical Trial Management Center, Kuma Hospital, Kobe 650-0011, Japan;
Department of Internal Medicine, Kuma Hospital, Kobe 650-0011, Japan;
Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;
Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;
Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;
Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;
Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;
Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;
Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;
Differentiated thyroid carcinoma; Metastasis; RAI-refractory; Prognosis;
机译:放射性碘治疗难治性转移灶出现后分化型甲状腺癌的预后及预后因素
机译:酪氨酸激酶抑制剂治疗放射性碘难治性复发分化型甲状腺癌患者疗效的临床因素
机译:分化良好的甲状腺癌接受初始放射性碘治疗后,术后甲状腺球蛋白水平升高的预后价值。
机译:碘全身体扫描,甲状腺球蛋白水平,〜(99m)Tc MIBI扫描和计算机断层扫描:来自分化型甲状腺癌的肺癌转移患者的结果
机译:尿RNA生物标志物预后肾细胞癌转移
机译:索拉非尼和Lenvatinib治疗放射性碘 - 难治性分化甲状腺癌的转移/复发
机译:转移难治性难治于放射性碘治疗后分化甲状腺癌的预后及预后因素
机译:甲状腺癌。术前诊断和预后因素